A recent study from Mammalian Genetics Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom; and School of Medicine, King’s College London, London, United Kingdom shows that “The deubiquitinase USP28 controls intestinal homeostasis and promotes …cancer.” This study was published in the August 1 2014 Journal of Clinical Investigantion (The number one journal in General clinical medicine) by Prof Axel Behrens‘s team.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Treating Intestinal cancer with an NIDDM drug: Acarbose inhibits the progression of intestinal tumors via down regulation of Ubiquitin Specific Peptidase 28 (USP28). This study suggests that Acarbose, by increasing the expression of its target gene, it may inhibit the progression of intestinal tumors. Together, this study suggests that pharmacological formulations encompassing“acarbose or its analogues” may be used to treat patients suffering from intestinal tumors.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Treating Intestinal cancer with an NIDDM drug: Acarbose inhibits the progression of intestinal tumors via down regulation of Ubiquitin Specific Peptidase 28 (USP28), 9/August/2014, 9.09 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
